, / Oncology Institute of Vojvodina, Sremska Kamenica / Medical Faculty, University of Novi Sad /Serbian Nuclear Medicine Society EANM/This

EANM/This Meeting is under the auspices of the EANM

; I /International Symposium on Molecular Imaging and Molecular Therapy; 1st Serbian Symposium on Hybrid Imaging and Molecular Therapy with International Participation
23. - 25. 2012. , , / April 23-25, 2012 Novi Sad, Serbia
/Venue Hotel Park (5* hotel), Novi Sad 23.-25. 2012/ April 23-25, 2012 / Novi Sad NAME of the corresponding author (Please write in Capital Letters) ADDRESS Designation Department TITLE PhD SURNAME DJOKI GIVEN NAME DIVNA

Laboratory for Radioisotopes

Name of the Institution

Vinca Institute of Nuclear Sciences, Belgrade

Address line-1 POBox 522, 11001 Address line-2 City Belgrade Country Serbia CONTACT Nos/ E -mail

Post Code 11000 Tel/Fax:

djokici@vinca.rs

+381118 066436

DEVELOPMENT OF THE PROCEDURES FOR PREPARATION AND QUALITY CONTROL OF 90Y-DOTATATE AND 177Lu-DOTATATE D.Djoki1, N.Nikoli1, Dj.Petrovi1, D.Stankovi1, V.Artiko2, M.Matovi3 1 Vinca Institute of Nuclear Sciences, Laboratory for Radioisotopes, University of Belgrade, PO Box 522, 11001 Belgrade, Serbia
2 3

Klinical Centre of Serbia, Institute for Nuclear Medicine , Belgrade, Serbia Klinical Centre of Kragujevac, Centre for Nuclear Medicine, Kragujevac, Serbia

Aim of study In recent years the number of patients with primary tumors is on dramatic increase in Serbia. In order to meet the requirements for future expansion and sustain the growth of the application of therapeutic radiopharmaceuticals, Vinca Institute have developed 90Sr/90Y generator system as well as the procedures for the preparation of 90Y-and 177Lu-DOTATATE, [90Y- or 177LuDOTA,Tyr3]octreotide, for treatment of the patient with neuroendocrine tumors. Methods
90

Sr/90Y generator system based on an electrochemical separation technique was developed. The radionulcidic purity of the 90Y solution was analyzed by paper and ITLC and extraction paper (EPC) chromatography. The labelling of peptide with 90YCl3 and 177LuCl3 was performed. The radiochemical purity was determined by HPLC with UV and radiometric detection and chromatorgaphic separation on C 18 Sep-Pak cartridges. The patients with various neuroendocrine tumors were treated with 90Y- or as well as 90Y/177Lu -DOTATATE cocktail. Results The labelling efficiency determined by chromatorgaphic separation was (0.790.58) % for 90YDOTATATE and (0.31-.18) % for 177Lu-DOTATATE. The analysis of the bremsstralung with 90Y-DOTATATE and SPECT and target scintigraphy with and 177Lu-DOTATATE was done. The results have shown that radiochemical purity of 90Y- and 177Lu-DOTATATE was high, the most frequently >99 %. The first results of clinical application of 90Y- or 177Lu-DOTATATE, as well as 90Y/177Lu -DOTATATE cocktail in the patient have shown beneficial effects on clinical symptoms without clinical side effects. Conclusion By using the proposed methodology we provide radiopharmaceuticals for clinical use for PRRT in Serbia. The first results in clinical application of these radiopharmaceuticals have shown that the treatment with 90Y- or 177Lu-DOTATATE, as well as 90Y/177Lu -DOTATATE cocktail could be useful for the management of patients with neuroendocrine tumors.
177

Lu-DOTATATE,